RTP Mobile Logo
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on the Management of Multiple Myeloma
Released March 2015

Proceedings from Part 2 of a 2-part satellite symposia series during the 56th ASH Annual Meeting. Featuring perspectives from Drs Rafael Fonseca, Morie A Gertz, Sagar Lonial, Gareth John Morgan and Noopur Raje. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    It is estimated that approximately 24,050 new cases of multiple myeloma (MM) were identified in the United States in the year 2014, and 11,090 individuals died from the disease. Of importance, currently more than 60 drug products are labeled for use in the management of hematologic malignancies, comprising more than 70 distinct FDA-approved indications. Although the extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies.

    These proceedings from a CME symposium during the 56th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology to frame a relevant discussion of the optimal management of MM. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for MM.

    • Appraise recent data on therapeutic advances and changing practice standards in multiple myeloma (MM), and integrate this information, as appropriate, into current clinical care.
    • Develop a treatment algorithm for symptomatic Waldenström macroglobulinemia incorporating newly approved agents.
    • Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
    • Customize the use of maintenance therapeutic approaches in the post-transplant and nontransplant settings on the basis of patient- and disease-related factors, including cytogenetic profile.
    • Effectively integrate the recently FDA-approved agents carfilzomib and pomalidomide into the nonresearch care of patients with MM.
    • Assess the ongoing clinical trials evaluating innovative investigational approaches for MM, and refer appropriate patients for study participation.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Rafael Fonseca, MD
    Getz Family Professor of Cancer
    Chair, Department of Internal Medicine
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: Amgen Inc, Celgene Corporation.

    Morie A Gertz, MD, MACP
    Roland Seidler Jr Professor of the Art of Medicine
    Chair, Department of Medicine
    Mayo Distinguished Physician
    Mayo Clinic
    Rochester, Minnesota

    Advisory Committee: Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi; Consulting Agreement: Celgene Corporation.

    Sagar Lonial, MD
    Professor of Medicine, University of Washington
    Member, Fred Hutchinson Cancer Research Center
    Director, Autologous Stem Cell Transplant Program
    Seattle, Washington

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi, Takeda Oncology.

    Gareth John Morgan, PhD
    Chairman, Department of Medical Therapeutics
    University of Athens School of Medicine
    Athens, Greece

    Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation; Consulting Agreements: Celgene Corporation, Takeda Oncology; Contracted Research: Celgene Corporation; Speakers Bureau: Novartis Pharmaceuticals Corporation.

    Noopur Raje, MD
    Director, Center for Multiple Myeloma
    Massachusetts General Hospital Cancer Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Amgen Inc, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary and Takeda Oncology.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals, an Amgen subsidiary and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

    Last review date: March 2015
    Expiration date: March 2016

Acknowledge and close

View video: